Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A 4-week, Double-Blind, Placebo-Controlled, Randomised, Parallel Group, Multi-Centre, Phase IIa Study to Investigate the Tolerability and Safety of 100 mg Oral AZD2423 in Patients With Moderate to Severe COPD

NCT01215279 is registered in ClinicalTrials.gov with AstraZeneca as lead sponsor.

NCT NCT01215279
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01215279 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A 4-week, Double-Blind, Placebo-Controlled, Randomised, Parallel Group, Multi-Centre, Phase IIa Study to Investigate the Tolerability and Safety of 100 mg Oral AZD2423 in Patients With Moderate to Severe COPD
Lead sponsor
AstraZeneca
Phase
Phase 2
Overall status
Completed
Start date
October 31, 2010
Completion date
March 31, 2011
Enrollment
63 (actual)
Sites
6

Conditions

As the registry lists them; a condition with its own page is linked.

chronic obstructive pulmonary disease, lung disease